The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple Sclerosis Society (NMSS) played a central role in many of the advances highlighted […] The post ECTRIMS 2025: NMSS funding, support drives progress in care appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Category: Multiple Sclerosis Research
GFAP and PIRA (ECTRIMS 2025)
Tweet The question of whether GFAP (Glial Fibrillary Acidic Protein), a marker of disease progression, is meaningful at the individual level is no longer unanswered. Data from the Swiss MS cohort presented at this years ECTRIMS show that although GFAP levels can fluctuate over time, the overall trajectory may be significant, particularly in individuals with…
Navigating Bladder and Bowel Dysfunction: A Community Perspective
Living with multiple sclerosis (MS) can be full of surprises. One of the toughest challenges for many people is dealing with bladder and bowel issues. These are things we don’t always feel comfortable talking about, but they’re a very real … Continue reading → Source: blog.mymsaa.org
ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years
Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of […] The post ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Spinal Tap II
Tweet No this has nothing to do with the legendary rubbish British Metal Mockumentary of the band Lumbar Puncture or something like that. It is not Spinal Tap Eleven as you turn up the volume but are we going to see the re-birth of the lumbar puncture. In some countries you get a spinal tap…
You can’t have half a relapse
Tweet In the animules the severity of disease is graded and so we see this or that cure of the Week being offered from the beasties as we see a mega claim for benefit on essentially a marginal difference in score. I have long said you can’t have half a relapse it is a relapse…
ECTRIMS 2025: Vidofludimus calcium shows promise against MS
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs […] The post ECTRIMS 2025: Vidofludimus calcium shows promise against MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS
Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in […] The post ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Why is response to cannabis variable ? It’s in your jeans and pumps…Beat yer to it!
Tweet Many years ago we showed that there was genetic control of entry of cannabinoids into the brains of mice. We linked the trait back to Swiss mice that arrived into the USA in 1926. There were two males and 5 female white mice that arrived at the Rockerfellow Institute in New York. They gave…
ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS
Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according […] The post ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com